| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
In a dose-dependent manner, Xanthinol Nicotinate (Xanthinol Niacinate; 2.76-276 µM; for 24 hours) suppresses the proliferation of HUASMC [2]. PDGFR mRNA and PDGFR-β levels on the HUASMC cell membrane are dose-dependently decreased by xanthinol Nicotinate (2.76-276 µM; for 24 hours) [2].
|
|---|---|
| ln Vivo |
Tumor pO2 is quickly and momentarily altered by Xanthinol Nicotinate (75 mg/kg; IP); the highest pO2 levels are achieved 10 to 30 minutes after Xanthinol Nicotinate administration [1]. Niacin Xanthinol has the ability to radiosensitize tumors (radiation response enhanced by 1.4) when 10 Gy of X-rays are delivered during tumor reoxygenation [1].
|
| Cell Assay |
Cell Proliferation Assay[2]
Cell Types: Human Umbilical Artery Smooth Muscle Cells (HUASMC) Tested Concentrations: 2.76, 27.6 or 276 µM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of HUASMC proliferation in a dose-dependent manner. Western Blot Analysis[2] Cell Types: HUASMC Tested Concentrations: 2.76, 27.6 or 276 µM Incubation Duration: 24 hrs (hours) Experimental Results: PDGFR mRNA and PDGFR-β levels on the HUASMC cell membrane were dose-dependently diminished. |
| Animal Protocol |
Animal/Disease Models: 5weeks old male NMRI mice [1]
Doses: 75 mg/kg Route of Administration: IP Experimental Results: Rapid and transient tumor pO2 changes and maximum pO2 values were obtained 10 to 30 minutes after XN administration. |
| References |
[1]. Segers J, et al. Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors. Int J Cancer. 2010 Jan 15;126(2):583-8.
[2]. Bai X, et al. Inhibited proliferation of human umbilical artery smooth muscle cells by xanthinol nicotinate. Med Biol Eng Comput. 2016 Jun;54(6):891-8. |
| Additional Infomation |
A vasodilator used in peripheral vascular disorders and insufficiency. It may cause gastric discomfort and hypotension.
|
| Molecular Formula |
C19H26N6O6
|
|---|---|
| Molecular Weight |
434.453
|
| Exact Mass |
434.191
|
| CAS # |
437-74-1
|
| PubChem CID |
9912
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
589.3ºC at 760 mmHg
|
| Melting Point |
180-184ºC
|
| Flash Point |
310.2ºC
|
| Vapour Pressure |
9.89E-15mmHg at 25°C
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
548
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(CCO)CC(CN1C=NC2=C1C(=O)N(C)C(=O)N2C)O.C1=CC(=CN=C1)C(=O)O
|
| InChi Key |
GEPMAHVDJHFBJI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H21N5O4.C6H5NO2/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2;8-6(9)5-2-1-3-7-4-5/h8-9,19-20H,4-7H2,1-3H3;1-4H,(H,8,9)
|
| Chemical Name |
7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid
|
| Synonyms |
NSC-113217; NSC 113217; Xanthinol niacinate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~575.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (115.09 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3018 mL | 11.5088 mL | 23.0176 mL | |
| 5 mM | 0.4604 mL | 2.3018 mL | 4.6035 mL | |
| 10 mM | 0.2302 mL | 1.1509 mL | 2.3018 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
